Advertisement CannaPharmaRx, PharmaDirections to start research & discovery program in Cannabinoid Science - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

CannaPharmaRx, PharmaDirections to start research & discovery program in Cannabinoid Science

CannaPharmaRx, the New Jersey-based pharmaceutical company, will be working with PharmaDirections, a pharmaceutical project management and consulting group, as it launches its R&D platform to investigate product opportunities in endocannabinoid science for ultimate commercialization in global markets.

PharmaDirections’ expertise will assist CannaPharmaRx with drug discovery, API process development, preclinical pharmacology and toxicology studies, formulation development, drug substance/drug product GMP manufacturing and regulatory submissions.

"CannaPharmaRx is pleased to have engaged such an experienced and diversified research and discovery advisory capability in assisting our product development leadership team in our initial R&D efforts," said Gerry Crocker, CEO, CannaPharmaRx, Inc.

CannaPharmaRx intends to research, develop and potentially commercialize a diverse line of cannabinoid-based products that will meet the needs of the healthcare providers serving various patient population needs.

Approved products will be labeled for medical indications, strengths, dosing and safety, as well as route of administration.

"We look forward to working with CannaPharmaRx," said Dr. Richard Soltero, President, PharmaDirections, Inc. "The identification of cannabinoid receptors has opened the path to new treatments for a wide array of diseases and we appreciate the opportunity to join in their cannabinoid development activities."

There is substantial pre-clinical evidence in the worldwide literature on the effects of cannabinoid substances in animal models. CannaPharmaRx has undertaken an in-depth analysis into the data to help determine which compounds may be further studied in additional animal models and to move selected compounds into early clinical evaluation in humans. CannaPharmaRx is not a ‘medical marijuana’ company.